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ABSTRACT
Background: KRAS mutation is common in human cancer. We assessed the clinical 
factors, including type of KRAS mutation and treatment, of patients with advanced 
cancer and tumor KRAS mutations and their association with treatment outcomes.
Methods: Patients referred to the Phase I Clinic for treatment who underwent 
testing for KRAS mutations were analyzed. 
Results: Of 1,781 patients, 365 (21%) had a KRAS mutation. The G12D mutation 
was the most common mutation (29%). PIK3CA mutations were found in 24% and 
10% of patients with and without KRAS mutations (p<0.0001). Of 223 patients 
with a KRAS mutation who were evaluable for response, 56 were treated with a 
MEK inhibitor-containing therapy and 167 with other therapies. The clinical benefit 
(partial response and stable disease lasting ≥ 6 months) rates were 23% and 9%, 
respectively, for the MEK inhibitor versus other therapies (p=0.005). The median 
progression-free survival (PFS) was 3.3 and 2.2 months, respectively (p=0.09). The 
respective median overall survival was 8.4 and 7.0 months (p=0.38). Of 66 patients 
with a KRAS mutation and additional alterations, higher rates of clinical benefit 
(p=0.04), PFS (p=0.045), and overall survival (p=0.02) were noted in patients treated 
with MEK inhibitor-containing therapy (n=9) compared to those treated with targeted 
therapy matched to the additional alterations (n=24) or other therapy (n=33). 
Conclusions: MEK inhibitors in patients with KRAS-mutated advanced cancer were 
associated with higher clinical benefit rates compared to other therapies. Therapeutic 
strategies that include MEK inhibitors or novel agents combined with other targeted 
therapies or chemotherapy need further investigation. 
INTRODUCTION
The KRAS gene, a Kirsten ras oncogene homolog 
from the mammalian ras gene family[1], encodes a protein 
that is a member of the small GTPase superfamily[2]. The 
KRAS protein exists in an active form (KRAS-ATP) and in 
an inactive form (KRAS-ADP), both of which are tightly 
controlled by the guanine nucleotide exchange factors 
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(GEFs) and GTPase-activating proteins (GAPs)[2-4]. 
KRAS is a key intracellular protein that activates multiple 
pathways, including the MAPK and PI3K pathways[5]. 
Mutant KRAS proteins are GAP-insensitive; 
therefore, the protein is constitutively GTP-bound, 
which leads to persistent and independent activation of 
the downstream effectors[4]. In addition, certain tumor 
types are associated with specific KRAS mutations, 
which differ in their carcinogenic potential[6-10]. The 
high frequency (up to 30%) of RAS mutation in human 
cancers[11] has stimulated the development of targeted 
agents against KRAS. Farnesyltransferase inhibitors, which 
were the first agents used to block the binding of RAS 
isoforms to the cancer cell membrane, had disappointing 
results[12-14]. In recent years, the focus has shifted to 
inhibiting the downstream signaling pathways of RAS. 
Clinical trials with MEK inhibitors as single agents 
and/or in combination with cytotoxic agents have been 
completed[15-19]. 
Mutations in the KRAS gene, which occur 
commonly in codons 12, 13, and 61, encode for a single 
amino-acid substitution. Emerging data demonstrate that 
each amino-acid substitution may affect the activity of 
KRAS differently, leading to a different affinity for the 
various downstream molecules[6]. For example, the G12D 
mutation encodes for a protein with high affinity for PI3K, 
while the G12C and G12V mutations activate RAS-like 
GTPase.
The clinical outcomes of patients with advanced 
cancer and KRAS mutations by type of codon and amino-
acid substitution have not been systematically explored. 
Therefore, we retrospectively reviewed data from patients 
with advanced cancer and KRAS mutations who were 
treated in the Phase I Clinical Trials Program at The 
Table 1: Baseline characteristics of patients with advanced cancer (any tumor type) who were tested for a 
KRAS mutation
Total Patients, 
N=1781
Wild-type KRAS, 
N=1416 (%)
Mutant KRAS, N=365 
(%) p
Age at Phase I Program 
presentation (median, range) 59 (4-90) 59 (4-90) 59 (20-84) 0.62
Sex 0.71
  Male 840 671 (80) 169 (20)
  Female 941 745 (79) 196 (21)
Race 0.03
  White 1339 1079 (80) 260 (20)
  African American 174 124 (71) 50 (29)
 Hispanic 162 127 (78) 35 (22)
  Asian 6 5 (83) 1 (17)
  Other 100 81 (81) 19 (19)
Type of cancer NA
  Colorectal 427 206 (48) 221 (52)
  Lung 188 140 (74) 48 (26)
  Pancreatic 47 19 (40) 28 (60)
  Endometrial 54 47 (87) 7 (13)
  Ovarian 156 144 (92) 12 (8)
  Other GI* 131 118 (90) 13 (10)
  Other GYN¤ 85 76 (89) 9 (11)
  Thyroid 36 34 (94) 2 (6)
  Other 657 632(96) 25(4)
Number of metastatic sites
   >2 518 386 (75) 132 (25) 0.0008
Number of prior therapies 
   Median (range) 4 (0-15) 4 (0-15) 3 (0-12) 0.53
* Gastrointestinal
¤ Gynecological
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University of Texas MD Anderson Cancer Center. Our 
objectives were to assess the clinical factors, including 
type of KRAS mutation and treatment, of patients with 
tumor KRAS mutations and their association with 
treatment outcomes.
RESULTS
Patient characteristics
Of the 1,781 patients, 365 (20.5%) were found to 
have a KRAS mutation. The clinical and demographic 
characteristics and tumor types of the patients with and 
without a KRAS mutation are shown in Table 1. Briefly, 
there was no difference in age (median, 59; p=0.62) or sex 
(male, 47.3% vs. 46.3%, respectively; p= 0.71) between 
the patients with wild-type and mutated KRAS. However, 
there was a significant difference in the percentage of 
patients with KRAS-mutated disease by race (African 
American 29%, Asian 22%, White 20%; p=0.03). The 
occurrence of KRAS mutations varied by tumor type, as 
summarized in Table 1 and Figure 1a. The most commonly 
analyzed tumor types were colorectal, lung, and ovarian 
cancer, reflecting the pattern of referrals to the Phase I 
Clinic (Figure 1b). Molecular analyses were performed on 
tumor samples from the primary site in 198 (54%) patients 
and from a metastatic site in 167 (46%) patients.
Patients with KRAS mutations were more likely to 
have more than two metastatic sites than patients with 
wild-type KRAS (36% vs. 27%, respectively; p=0.0008). 
No difference in the number of prior therapies was noted 
between patients with wild-type and mutated KRAS 
(p=0.53). 
Specific KRAS mutations and other alterations 
The distribution of specific KRAS mutations by 
tumor type is summarized in Table 2. Overall, mutations 
in codons 12 and 13 were the most common. The G12D 
Table 2: Distribution of KRAS mutations by tumor type
KRAS Mutation CRC* (%) Lung (%) Pancreatic (%) Other (%) Total
G12D 68 (31) 8 (17) 12 (43) 18 (26) 106 (29)
G12V 51 (23) 10 (21) 6 (21) 13 (19) 80 (22)
G12C 13 (6) 19 (40) 0 9 (13) 41 (11)
G13D 29 (13) 2 (4) 0 9 (13) 40 (11)
G12A 15 (7) 4 (8) 0 6 (9) 25 (7)
G12S 14 (7) 1 (2) 0 0 15 (4)
Q61H 6 (3) 2 (4) 1 (4) 5 (7) 14 (4)
G13C 2 (1) 1 (2) 0 1 (1) 4 (1)
Other 16 (7) 0 8 (29) 7 (10) 40 (11)
Unknown 7(3) 1 (2) 1 (4) 0 9 (2)
Total 221 48 28 68 365
*Colorectal cancer
Table 3: Distribution of other molecular alterations by KRAS mutational status
Total, n= 1781 Wild-type KRAS, n= 1416
Mutant KRAS, n= 
365 P
No. of associated alterations
   Median (range) 0 (0-9) 0(0-9) 1(1-9) <0.0001
   >2 118 81(6%) 37 (10%) 0.0025
Type of associated alterations
   PI3KCA 162/1386 (12%) 118/1203 (10%) 44/183 (24%) <0.0001
   P53 184/510 (36%) 155/427 (36%) 29/83 (35%) 0.87
   PTEN 132/1040 (13%) 111/881 (13%) 21/159 (13%) 0.83
   BRAF 77/1370 (6%) 76/1139 (7%) 1/231 (0.4%) 0.0002
   EGFR 54/1205 (5%) 49/1022 (5%) 5/183 (3%)* 0.21
   MET 41/951(4%) 32/786 (4%) 9/165 (5.5%) 0.43
* Four patients had an EGFR mutation and one patient had EGFR overexpression
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Table 4: Clinical outcomes of patients with KRAS mutations
Therapy Evaluable
PR+SD≥6 
Months 
(RECIST)
P Median PFS, months P
Median 
Survival, 
months
P
KRAS mutation  0.60 0.57 0.07
 G12A Any 10 0 (0%) 1.9 4.4
 G12C Any 20 2 (10%) 2.6 8.4
 G12D Any 44 7 (16%) 2.2 8.0
 G12V Any 35 7 (20%) 2.3 8.6
 G13D Any 20 3 (15%) 2.2 7.0
 Other Any 23 2 (9%) 2.1 6.8
Patients with KRAS 
mutation alone
 Colorectal MEK-containing 12 1 (8%) 0.54 1.9 .94 5.7 0.06
Other 73 4 (5%) 2.1 7.5
 Lung MEK-containing 23 4 (17%) 1.00 3.2 .71 7.9 0.13
Other 10 2 (20%) 3.2 17.6
 Pancreas MEK-containing 5 2 (40%) 0.07 11.0 .08 14.4 0.27
Other 12 0 (0%) 1.9 4.5
 Other 
tumors MEK-containing 7 4 (57%) 0.34 7.7 .44 12.1 0.54
Other 15 4 (27%) 2.2 9.8
 Total 
KRAS mutation 
alone
MEK-containing 
Other
47
110
11 (23%)
10 (9%) 0.02
2.8
2.1 .10
8.0
7.5 0.59
Patients with KRAS 
and other molecular 
alterations§
0.044 0.09 0.02
MEK-containing 9 2 (22%) 3.6 Not reached
Targeted therapy 
matched the other 
alterations¤
24 0 2.0 4.4
Other, non-matched 33 5 (15%) 2.8 6.8
Total KRAS* 
mutation
MEK-containing 
vs.
Other
56
167
13 (23%)
15 (9%)
0.005
3.3
2.2
0.09
8.4
7.0
0.38
§ The total number of patients with KRAS and other molecular alterations was 69 (66 were evaluable for response; all 69 
patients were evaluable for PFS and OS).  
¤ All the targeted therapy matching the other alterations were inhibitors of the PI3K/AKT/mTOR pathway. 
* The total number of patients who received MEK was 60 (56 patients were evaluable for response; however, all 60 patients 
had data for PFS and OS). The total number of patients who received other therapy was 177 (167 had clinical benefit data; all 
176 had data for PFS and OS). 
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mutation was the most common mutation overall (29%) in 
all tumor types except for lung cancer, in which G12C and 
G12V were more frequent. No G12C or codon 13 (G13D, 
G13C, G13R, and G13V) mutations were noted in the 28 
patients with pancreatic cancer.
Among the 365 patients with KRAS mutations, 
256 (70%) were found to have tumors harboring KRAS 
mutations without any other molecular alterations. 
Alternatively, 109 (30%) patients were found to have 
tumors with ≥1 additional molecular alterations. The 
distribution of the various additional molecular alterations 
in both mutated and wild-type KRAS is summarized in 
Table 3. The number of additional molecular alterations 
was higher in mutated KRAS than in wild-type KRAS. The 
most frequently tested alterations were PI3KCA, BRAF, 
and EGFR; the most common alterations found in both 
wild-type and mutant KRAS tumors were PI3KCA, p53, 
and PTEN. A higher percentage of patients with mutated 
KRAS had PIK3CA mutations compared to patients with 
wild-type KRAS (24% vs. 10%, respectively; p<0.0001). 
In contrast, more patients with wild-type KRAS had BRAF 
mutations compared with patients with mutated KRAS (7% 
vs. 0.4% respectively; p=0.0002).
Outcomes of patients with KRAS mutations 
Best response by RECIST, PFS, and survival by 
specific KRAS mutation, tumor histology, and type of 
therapy are shown in Table 4. The clinical outcomes varied 
with the specific mutation (for instance, patients with the 
G12A mutation appeared to have poorer outcomes than 
those with other mutations), but the differences were not 
statistically significant (p=0.07) (Figure 2a). 
Univariate and multivariate analyses of the 
prognostic significance of baseline characteristics 
of patients with KRAS mutations are summarized in 
Supplemental Table 1. Briefly, previously reported 
prognostic covariates (lactate dehydrogenase level, 
serum albumin level, number of metastatic sites, and 
ECOG performance status) for patients with advanced 
cancer treated on phase I clinical trials were confirmed 
in this analysis. Furthermore, the presence of additional 
mutations was found to be a good prognostic feature (HR: 
0.7; p=0.03). Interestingly, after adjustment for other 
variables, G12V was found to be associated with longer 
survival compared to G12A (p=0.008; Supplemental Table 
1).
Outcomes of patients with KRAS mutations by 
therapy 
The median number of phase I trials that patients 
with a KRAS mutation were treated on was one (range, 
1-5). Clinical outcomes, including clinical benefit (partial 
response and stable disease ≥ 6 months per RECIST), PFS, 
and OS, are summarized in Table 4. Of 365 patients with 
KRAS mutations, 223 were evaluable for response. The 
other patients were excluded for the following reasons: 
loco-regional therapy (n=54), decline in performance 
status (n=28), consent withdrawal (n= 14), loss of follow-
up (n=11), early toxicity (n=8), or other (n=27). 
Of 157 patients with a KRAS mutation and no 
additional known alterations, 47 received a MEK 
inhibitor--containing therapy and 110 received non-
MEK inhibitor therapy including another targeted agent, 
chemotherapy, or both. In subset analyses by tumor type, 
no significant difference was noted in outcomes between 
patients treated with a MEK inhibitor--containing therapy 
and those treated with other therapies. However, a 
trend towards a higher rate of clinical benefit was noted 
in patients with pancreatic cancer treated with MEK 
inhibitor--containing therapy compared to other therapies 
(p=0.07). When the total number of patients with a KRAS 
Figure 1: a. Proportion of KRAS mutations by tumor type in patients tested for KRAS mutations. b. Distribution of tumor types in 
patients with KRAS mutations (n=365)
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mutation was analyzed regardless of tumor type, the rate 
of clinical benefit of patients treated with a MEK inhibitor-
-containing therapy was higher than that of those treated 
with other therapies (p=0.02). 
Of 66 patients with KRAS mutations and other 
molecular alterations, nine received a MEK inhibitor-
-containing therapy, 24 received therapies matched 
with other alterations (all targeted against alterations in 
the PI3K/AKT/mTOR pathway), and 33 received non-
matched therapies. The overall clinical benefit rates were 
22%, 0%, and 15%, respectively (p=0.04). In addition, 
patients who received a MEK inhibitor--containing 
therapy had longer PFS (p=0.09) and longer overall 
survival (p=0.02) compared to the other treatment groups 
(Figure 2b and 2c). 
When all 223 patients with a KRAS mutation with 
or without an additional alteration were included in 
the analysis, MEK inhibitor-containing therapy had a 
statistically significantly higher rate of clinical benefit 
compared to other therapies (23% vs. 9%, respectively; 
p=0.005). A trend towards longer PFS was also noted in 
the MEK inhibitor group compared to others (p=0.09). No 
difference in overall survival was noted (p=0.38). 
Of the 60 patients who received a MEK inhibitor--
containing therapy, 35 also received a PI3K/AKT/mTOR 
pathway inhibitor, 17 received a MEK inhibitor only, and 
eight also received other targeted or cytotoxic therapy. 
Their respective median OS were 17, 8.2 and 7.9 months 
(p=0.054) (Figure 2d). 
DISCUSSION
To our knowledge, this is the first systematic 
analysis of the clinical outcomes of patients with KRAS 
mutations treated on phase I clinical trials. We found that 
KRAS mutations vary by tumor type. This heterogeneity 
in amino acid substitution is thought to be associated with 
differences in the clinical course of the disease. The use of 
MEK inhibitors in patients with KRAS-mutated advanced 
cancer was associated with higher clinical benefit rates 
compared to other therapies. 
In our series, the proportion of tested patients with 
pancreatic cancer with KRAS mutation was similar to 
that reported in the COSMIC database[20]. However, the 
proportions of tested patients with colon and lung cancers 
with KRAS mutation were slightly higher than published 
Figure 2: a. Overall survival by KRAS mutation types . b. Progression free survival of patients with KRAS and other molecular 
aberrations by treatment type. c. Overall survival of patients with KRAS and other molecular aberrations by treatment type. d. 
Overall survival of patients treated with MEK inhibitor containing trials by type of therapy 
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data, perhaps in part reflecting the referral pattern in 
our Phase I Program, which may be affected by the 
availability of MEK inhibitor trials. This discrepancy can 
also be explained by differences in the detection method, 
histology subtypes, disease stage, and other factors.
Our analysis showed that KRAS mutation by specific 
amino acid substitution varies by tumor type. The specific 
KRAS mutations in colorectal cancer were similar to those 
previously reported in a smaller series, in which G12D 
and G12V were the two most commonly seen mutations 
[21]. Furthermore, the various specific KRAS mutations 
seen in lung cancer in our patient group were similar to 
those previously reported [22]. 
One of the intriguing findings of our analysis 
was the association of the KRAS G12V mutation with 
longer survival compared with the KRAS G12A mutation 
(p=0.008; Supplemental Table 1). This appears to be in 
line with preclinical and clinical studies demonstrating 
that specific KRAS mutations are associated with 
heterogeneous outcomes [22-24].
In our analysis, the use of MEK inhibitors was 
associated with an improved clinical benefit rate compared 
with other therapies in patients with a KRAS mutation 
(23% vs. 9%; p=0.005) (Table 4). This better disease 
control with MEK inhibitor-containing trials translated 
into a trend toward longer PFS in the MEK inhibitor 
group compared with others (3.3 vs. 2.2 months; p=0.09). 
However, no statistical difference in overall survival was 
noted between the two groups (8.4 vs. 7 months, p=0.38), 
perhaps because patients were treated with subsequent 
therapies. In addition to the relatively small number 
of patients, the short PFS seen in our analysis may be 
explained by the poor-prognosis patient population, the 
development of resistance to MEK inhibitors, or the 
development of other driver alterations by the time the 
patients started on treatment (archival tissue was used 
for molecular profiling in most patients). Our results are 
compatible with emerging data demonstrating that MEK 
inhibitors have promising antitumor activity in patients 
with KRAS-mutated cancer[18]. 
We also found that the presence of other molecular 
alterations in addition to KRAS alterations was associated 
with longer survival (Supplemental Table 1). The reason 
is unknown, but the numbers of patients with a KRAS 
mutation and 1 or ≥2 additional molecular alterations were 
too small compared to patients with a sole KRAS mutation 
(72, 37, and 256 patients, respectively) to draw meaningful 
conclusions. Clinical studies should explore the clinical 
significance of additional alterations in patients with tumor 
KRAS mutations. For instance, additional alterations may 
partially negate the effects of the KRAS mutation. 
These results are hypothesis-generating, since they 
were derived from a retrospective analysis and not from 
a randomized trial. Therefore, one cannot distinguish 
between the prognostic value and the predictive value of 
certain types of KRAS mutations. 
Our data also demonstrated that patients with KRAS 
mutations had a higher proportion of PI3KCA alterations 
than patients with wild-type KRAS (24% vs. 10%, 
respectively; p<0.0001) and that patients with wild-type 
KRAS had a higher proportion of BRAF mutations than 
patients with KRAS mutations (7% vs. 0.4%, p=0.0002) 
(Table 3). The coexistence of PI3K and KRAS mutations 
and the mutual exclusion of KRAS and BRAF mutations 
had been previously reported in a subset of patients 
with colorectal cancer [25, 26]. Furthermore, KRAS and 
EGFR mutations coexisted in 4 patients (2 patients with 
pancreatic cancer, 1 with CRC and 1 with NSCLC). 
Various reports showed that KRAS and EGFR mutations 
are mutually exclusive in patients with lung cancer[27-30]; 
however, some cases were previously reported to harbor 
both EGFR and KRAS mutations[31-33]. 
In both preclinical and clinical settings, the co-
existence of both KRAS and PI3KCA alterations was 
reported to be a negative predictor of response to PI3K 
inhibitors[26, 34-37] and MEK inhibitors[38]. Both PI3K/
AKT/mTOR and RAS/RAF/MEK/ERK are downstream 
pathways of the KRAS protein[39, 40]. Our data showed 
that treatment with a MEK inhibitor resulted in better 
outcomes than treatment with PI3K pathway inhibitors. 
Other investigators have demonstrated that tumors in 
xenograft models with both PI3K and KRAS molecular 
alterations regressed upon MEK inhibition and had a 
less-pronounced response to PI3K inhibition[41], perhaps 
suggesting that KRAS mutation may represent the driver 
mutation. Whether the combination of MEK and PI3K 
inhibitors is associated with better outcomes than either 
inhibitor alone is currently being investigated in clinical 
trials.
Our analysis has several limitations, which are 
typical for retrospective analyses for patients with any 
tumor type treated with targeted therapy based on genetic 
alterations. These limitations include relatively small 
numbers of patients with specific targetable alterations 
per tumor type, not including alterations other than KRAS 
mutations that can activate the MAPK pathway (as such 
alterations were not tested routinely in CLIA-certified 
laboratories), and various dose levels and various drugs 
used in the analyses, resulting in large tested hypotheses 
that cannot rule out false positive conclusions. 
Prospective studies assessing the prognostic 
significance of various KRAS mutations will help 
elucidate the role of KRAS in human carcinogenesis. The 
development of novel agents for treating patients with 
KRAS mutations and therapeutic strategies that include 
novel agents combined with other targeted therapies, 
chemotherapy and/or immunotherapy is urgently needed. 
In this direction, the National Cancer Institute is launching 
a large-scale project to develop therapeutic strategies 
against cancers driven by RAS with the contribution of 
national scientific leaders and using core facilities and 
modern technology. 
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METHODS
Patients
We identified 1,781 consecutive patients with 
advanced cancer who were referred to the Phase I Clinical 
Trials Program at The University of Texas MD Anderson 
Cancer between November 2006 and March 2013 and 
who had undergone tumor molecular analysis for KRAS 
mutations as part of molecular profiling. Patients referred 
to the Phase I Clinic were of various ages, had advanced/
metastatic cancer that was refractory to standard therapy 
or had relapsed after standard therapy, or had a tumor 
for which there was no standard therapy available. All 
protocols in the Phase I Clinical Trials Program required 
that participants have evidence of evaluable or measurable 
disease according to Response Evaluation Criteria in Solid 
Tumors (RECIST) guidelines[42, 43] and an Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0-2. Additional eligibility criteria varied according to 
the protocol on which the patient was enrolled. All patients 
provided written informed consent prior to enrollment onto 
a trial. All trials, as well as this analysis, were performed 
with the approval of and in accordance with the guidelines 
of the MD Anderson Cancer Center Institutional Review 
Board. 
Analysis of molecular alterations 
Molecular profiling had been performed in a 
Clinical Laboratory Improvement Amendments (CLIA)-
certified Molecular Diagnostics Laboratory, as previously 
described[44] or at Foundation Medicine, Inc. 
Therapy
Treatment was selected as previously described[44]. 
Briefly, patients whose tumors had a molecular aberration 
were preferably treated on a clinical trial with a matched 
targeted agent, when available. The allocation of patients 
to investigational treatment varied according to protocol 
availability, eligibility criteria, histologic diagnosis, the 
patient’s prior response to therapy, potential toxicity, 
insurance coverage, and patient preference or physician 
choice. Patients treated with regional therapy were 
excluded from the outcome analysis.
The patients with tumors harboring KRAS mutations 
were treated with MEK inhibitor-containing therapy when 
a clinical trial was available. Patients were treated in the 
following clinical trials if the eligibility criteria were 
met: NCT01138085, NCT00454090, NCT01378377, 
NCT00687622, NCT01155453, and NCT01337765. If ≥ 2 
molecular alterations were present, patients were treated in 
a matched trial that targeted both alterations, if available. 
The types of treatment were categorized as (a) 
MEK inhibitor--containing therapy or (b) other therapies 
(targeted therapy with or without cytotoxic agents). If an 
additional alteration to the KRAS mutation was present, the 
treatment was categorized as follows: (a) MEK inhibitor--
containing therapy, (b) targeted therapy for the additional 
alteration, when applicable, or (c) other therapies.
Endpoints and statistical methods
Best response was assessed using imaging 
studies performed every two cycles (1 cycle = 3-4 
weeks, depending on the protocol) by an MD Anderson 
radiologist. Tumor measurements were confirmed 
independently by a physician in the response assessment 
clinic within our department using RECIST guidelines 
applicable at the time of the patient’s response assessment. 
Clinical benefit (CB) from any therapy was defined as 
complete response (CR) or partial response (PR) or stable 
disease (SD) for ≥ 6 months. Progression-free survival 
(PFS) was measured from the first day of treatment on 
a clinical trial until the patient came off study because 
of disease progression or death, whichever came first. 
Overall survival (OS) was measured from initiation of 
treatment on a clinical trial until death from any cause or 
last follow-up.
Patients’ characteristics at the time of presentation 
in the Phase I Clinic were analyzed using descriptive 
statistics. Categorical data were described using 
contingency tables, including counts and percentages. 
Continuously scaled measures were summarized 
by median and range. The association between two 
categorical variables was examined using the chi-squared 
test. Survival and PFS were estimated using the Kaplan-
Meier method, and survival was compared between groups 
using the two-sided log-rank test. Survival and PFS were 
analyzed based on the specific type of KRAS mutation and 
the type of treatment. Statistical analyses were carried 
out using TIBCO Spotfire S+ 8.2 for Windows (TIBCO 
Software, Inc.).
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